Novo Nordisk A/S
NONOF
$47.49
-$1.18-2.42%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.77% | 19.05% | 15.76% | 28.79% | 22.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.77% | 19.05% | 15.76% | 28.79% | 22.51% |
| Cost of Revenue | 36.04% | 31.81% | 25.94% | 24.80% | 17.47% |
| Gross Profit | 7.19% | 16.78% | 13.94% | 29.46% | 23.51% |
| SG&A Expenses | 0.98% | 23.49% | 8.30% | 7.77% | 18.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 105.99% | -102.39% | -137.08% | 203.99% |
| Total Operating Expenses | 18.31% | 25.63% | 13.63% | 15.42% | 18.89% |
| Operating Income | 4.52% | 11.47% | 18.01% | 45.90% | 26.81% |
| Income Before Tax | -21.11% | 40.68% | 12.40% | 27.44% | 23.63% |
| Income Tax Expenses | -17.29% | 45.74% | 19.02% | 28.22% | 27.97% |
| Earnings from Continuing Operations | -22.10% | 39.35% | 10.71% | 27.24% | 22.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.10% | 39.35% | 10.71% | 27.24% | 22.55% |
| EBIT | 4.52% | 11.47% | 18.01% | 45.90% | 26.81% |
| EBITDA | 8.23% | 17.87% | 21.43% | 44.43% | 22.85% |
| EPS Basic | -21.95% | 39.80% | 11.21% | 27.77% | 23.22% |
| Normalized Basic EPS | 8.69% | 15.21% | 12.91% | 38.60% | 24.33% |
| EPS Diluted | -21.83% | 39.93% | 11.38% | 27.85% | 23.50% |
| Normalized Diluted EPS | 8.82% | 15.33% | 13.02% | 38.69% | 24.41% |
| Average Basic Shares Outstanding | -0.20% | -0.32% | -0.45% | -0.41% | -0.55% |
| Average Diluted Shares Outstanding | -0.31% | -0.42% | -0.54% | -0.49% | -0.63% |
| Dividend Per Share | -- | 12.95% | -- | 22.20% | -- |
| Payout Ratio | 0.46% | -- | 0.08% | -- | -0.04% |